27 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
26 Sep 23
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
8:30am
C et al. Candel Virtual R&D Day, December 2022). These data were further confirmed in the current update.
Highlights as of August 1, 2023 data
8-K
EX-99.1
CADL
Candel Therapeutics Inc
13 Jun 23
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in late-stage NSCLC
8:31am
after follow up, and significantly decrease the monthly rate of tumor growth (Aggarwal C et al. Virtual R&D Day, December 2022). These data supported
8-K
gqkfzkx5
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
8-K
EX-99.1
6m922moqi6f1
17 Apr 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Non-Small Cell Lung Cancer
8:30am
8-K
EX-99.1
7cisw
30 Mar 23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
8:30am
8-K
q91u0ty4hzfj
6 Dec 22
Other Events
5:30pm
8-K
EX-99.1
m8yjkj922
6 Dec 22
Other Events
5:30pm
8-K
63o13dtknbg
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
EX-99.1
mwidk9q
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
gn1e3
29 Nov 22
Regulation FD Disclosure
8:31am
8-K
EX-99.1
uvjr28vaup07v
29 Nov 22
Regulation FD Disclosure
8:31am
8-K
EX-99.1
1h9xed31x94qbc8t34oe
10 Nov 22
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
8:30am
DEF 14A
xu99b 58t7veusy0crek
2 Sep 22
Definitive proxy
8:30am
10-K
v2k9mkvoxkuiinq2
29 Mar 22
Annual report
8:46am